Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

NCT02929823 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
130
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Senju Pharmaceutical Co., Ltd.